v3.26.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 50,644 $ 47,872
Short-term investments 40,674 41,106
Accounts receivable, net 347 216
Inventories 3,384 3,743
Prepaid expenses and other current assets 1,776 6,136
Total current assets 96,825 99,073
Long-term investments 4,012 20,160
Other assets 241 361
Total assets 101,078 119,594
Current liabilities:    
Accounts payable 7,510 3,745
Accrued and other current liabilities 23,112 20,183
Deferred revenue 5,418 5,314
Total current liabilities 36,040 29,242
Product development obligations 0 19,560
Deferred revenue, net of current 2,620 255
Liability related to sale of future revenues, non-current 70,495 65,980
Other long-term liabilities 67 82
Total liabilities 109,222 115,119
Commitments and Contingencies (Note 10)
Redeemable non-controlling interests 21,480 21,480
Stockholders' deficit:    
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at June 30, 2026 and December 31, 2025
Common stock, $0.01 par value; 225,000 shares authorized at June 30, 2026 and December 31, 2025; 4,049 and 4,047 shares issued and outstanding at June 30, 2026 and December 31, 2025 41 1,012
Additional paid-in capital 1,680,274 1,677,179
Accumulated other comprehensive loss (1,188) (2,182)
Accumulated deficit (1,709,271) (1,706,047)
Total stockholders' deficit attributable to Kyntra Bio (30,144) (30,038)
Nonredeemable non-controlling interests 520 13,033
Total deficit (29,624) (17,005)
Total liabilities, redeemable non-controlling interests and deficit $ 101,078 $ 119,594